Nerdwallet Inc vs Relay Therapeutics Inc. Common Stock — how do they compare? Nerdwallet Inc trades at $10.01 (market cap $625.17M), while Relay Therapeutics Inc. Common Stock trades at $17.62 (market cap $3.82B). The key difference: Relay Therapeutics Inc. Common Stock is far larger — about 6.1× Nerdwallet Inc's market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| NRDS | RLAY | |
|---|---|---|
Market Cap | $625.17M | $3.82B |
Volume | 1,321,316 | 4,332,079 |
Sector | Media | Health |
52-Week High | $15.93 | $20.75 |
52-Week Low | $7.58 | $6.03 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $539.47M | $2.93B |
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.085, up 2.54% with bullish technical indicators and strong fundamental momentum. The company shows impressive revenue growth from $539M in 2022 to $837M in 2025, with net income turning positive to $48.7M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, but Q1 and Q4 2025 beat estimates. Analyst consensus remains positive with 4 buy ratings out of 6, and technical analysis shows bullish signals across moving averages and oscillators.
Outlook remains favorable with projected 2026 revenue of $860M and net income of $65M, though Q2 earnings miss and high RSI suggest near-term caution. The stock offers attractive valuation with P/E of 10.87 and P/S of 0.81, but faces risks from organic search pressure in key product categories and macroeconomic sensitivity.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →